Bone marrow and stem cellUmbilical Cord Blood-Derived Stem Cells Spontaneously Express Cardiomyogenic Traits
Section snippets
Collection of UCB, Isolation, and Cell Culture of UCBSCs
A total of 25 UCB samples (60–100 mL) were collected from the umbilical cord vein and processed within 12 hours after extraction. Cells were isolated according to modifications of a previously reported method.2 Blood cells clarified by previous centrifugation were resuspended in 30 mL calcium- and magnesium-free phosphate-buffered saline (PBS) (Invitrogen). The cell suspension layered over 1.077 g/mL Lymphoprep (Nycomed) was centrifuged at 400g for 30 minutes. Mononuclear cells recovered by
Results
The study included 25 UCB samples that were analyzed for their capacity to generate primary cultures of UCBSCs. Four primary cultures of UCBSCs were satisfactorily generated (16%). After selection and plating of mononuclear cells, a few elongated fibroblast-like cells attached to the plastic culture dishes were present within 4 weeks and expanded rapidly (Fig 1A, B). Primary cultures were maintained uninterruptedly over 4 months and 10 passages.
Induction of UCBSCs with adipogenic and osteogenic
Discussion
This study demonstrated that UCBSCs exhibited some cardiomyogenic lineage markers during in vitro culture in the absence of cardiac induction factors.
The advent of stem cell biology has provided a good option to test UCBSC’s properties and therapeutic application in myocardial regeneration. Thus, the foundation for the view of the heart as a terminally differentiated post-mitotic organ, which had profoundly conditioned basic and clinical research in cardiology, has been certainly rejected.8
Acknowledgments
The authors gratefully appreciate Berta Raposo for technical assistance in flow cytometry.
References (11)
- et al.
Compactin enhances osteogenesis in murine embryonic stem cells
Biochem Biophys Res Commun
(2001) - et al.
Identification of cardiomyogenic lineage markers in untreated human bone marrow-derived mesenchymal stem cells
Transplant Proc
(2005) - et al.
Myocardial-cell replacement: the science, the clinic and the future
Nat Clin Pract Cardiovasc Med
(2004) - et al.
A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential
J Exp Med
(2004) - et al.
Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury
Stem Cells Dev
(2005)
Cited by (46)
Stem Cell Therapy in Single-Ventricle Physiology: Recent Progress and Future Directions
2021, Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery AnnualCitation Excerpt :In fact, UCB-MSCs have demonstrated superior ex vivo expansion.16 Early in vitro expansion and characterization established expression of proteins important for cardiac regeneration (connexin-43, sarcoendoplasmic reticulum calcium transport ATPase 2, and stromal cell-derived factor-1α [SDF-1α).15 In addition to the classic MSC lineages, UCB-MSCs are capable of differentiating into many cell types including hepatocyte-like cells, neuroglial-like cells, respiratory epithelial cells, and cardiomyocytes.17-19
Umbilical cord blood-derived mesenchymal stem cells: New therapeutic weapons for idiopathic dilated cardiomyopathy?
2014, International Journal of CardiologyCitation Excerpt :The most marked limitation in the use of UCB is its low progenitor cell concentration, albeit transplantation of double partially HLA-matched UCB units is recognized as a simple approach for overcoming cell dose limitation [73]. As mentioned above UCB also contains MSCs [74], which play key roles in the regulation of blood vessel formation [75]. UCBMSCs were initially characterized as spontaneously exhibiting cardiomyogenic traits, such as abundant expression of α-actinin, connexin-43, and SERCA-2 [74].
Forty Years of Publication of Transplantation Proceedings—The Fourth Decade: Globalization of the Enterprise
2011, Transplantation ProceedingsModifying strategies for SDF-1/CXCR4 interaction during mesenchymal stem cell transplantation
2022, General Thoracic and Cardiovascular SurgeryMesenchymal stem cells for cardiac repair: Are the actors ready for the clinical scenario?
2017, Stem Cell Research and Therapy
This work was supported by grants from Ministerio de Educación y Ciencia (SAF 2004-08044-C03-01). We also appreciate support from BMS, Fundación Daniel Bravo Andreu, and Fundación Roviralta.
- 1
C. Prat-Vidal and S. Roura contributed equally to this work.